Hepatitis C Treatment Could Be Shortened to 8 Weeks: Atea Phase 3 Trial Matches Epclusa

Chronic hepatitis C can now usually be cured with oral antiviral drugs, so the next stage of competition is not only about whether the virus can be cleared, but also whether treatment duration and the burden on patients can be reduced. Phase 3 results announced by Atea Pharmaceuticals show that its bemnifosbuvir/ruzasvir combination regimen achieved a virologic response similar to that of Gilead Sciences’ Epclusa with a shorter course of treatment.

The C-BEYOND trial enrolled 905 patients with chronic hepatitis C and randomly compared fixed-dose bemnifosbuvir/ruzasvir with sofosbuvir/velpatasvir, the components of Epclusa. Atea said the proportions maintaining viral clearance 12 weeks after treatment were 93.9% and 94.8%, respectively, and the statistical analysis met the criterion for non-inferiority. This measure is commonly known as SVR12 and is the core endpoint used to determine treatment success in hepatitis C trials.

Treatment duration is the study’s most distinctive design feature. According to the trial registry, participants without cirrhosis received 8 weeks of bemnifosbuvir/ruzasvir, while those with compensated cirrhosis were treated for 12 weeks. The control group received 12 weeks of Epclusa regardless of cirrhosis status. Atea said the SVR12 rate among patients without cirrhosis who received the 8-week experimental regimen was 93.5%, meeting the prespecified secondary endpoint.

If subsequent analyses confirm that efficacy extends across different viral genotypes and patient subgroups, taking medication for 4 fewer weeks could improve convenience and may also affect costs and market competition. However, the benefit of a shorter treatment course currently applies only to the trial population without cirrhosis; patients with compensated cirrhosis still require 12 weeks of treatment, and the results cannot be generalized to mean that treatment can be shortened for all patients with hepatitis C.

At this stage, these data remain preliminary results announced by the company. ClinicalTrials.gov lists C-BEYOND as a Phase 3, randomized, controlled study that began in April 2025 and is currently active but no longer recruiting; as of the publication of the related announcement, formal results had not yet been posted on the registry page. Efficacy across subgroups, treatment failures, discontinuations, and complete safety data still await more detailed academic publication or regulatory documents.

The results therefore primarily demonstrate that bemnifosbuvir/ruzasvir has a basis for further submission and review, rather than that it has already replaced the current standard of care. Whether it can truly change clinical choices will depend on the complete safety data, consistent performance in difficult-to-treat populations, and how regulators assess the real-world value of an 8-week course relative to an established 12-week regimen.